Gilles Bernard Tremblay
Hoofd Techniek/Wetenschap/O&O bij Alethia Biotherapeutics, Inc.
Profiel
Gilles Bernard Tremblay is currently the Vice President-Research at Alethia Biotherapeutics, Inc. He started this position in 2012.
Previously, he worked as a Group Leader at SignalGene, Inc. Dr. Tremblay holds a doctorate degree from McGill University.
Actieve functies van Gilles Bernard Tremblay
| Bedrijven | Functie | Begin |
|---|---|---|
Alethia Biotherapeutics, Inc.
 Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | Hoofd Techniek/Wetenschap/O&O | 01-01-2000 |
Eerdere bekende functies van Gilles Bernard Tremblay
| Bedrijven | Functie | Einde |
|---|---|---|
| SignalGene, Inc. | Corporate Officer/Principal | - |
Opleiding van Gilles Bernard Tremblay
| McGill University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Alethia Biotherapeutics, Inc.
Alethia Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alethia Biotherapeutics, Inc. discovers and develops therapeutic mAbs against highly-disease tissue specific novel clinically-relevant targets. The firm focuses on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition. The company was founded in 2002 by Mario Filion and Yves Cornellier and is headquartered in Montreal, Canada. | Health Technology |
| SignalGene, Inc. |
